


Lenalidomide sodium

Cat. No.:	HY-A0003C
Molecular Formula:	C ₁₃ H ₁₃ N ₃ NaO ₃
Molecular Weight:	282.25
Target:	Ligands for E3 Ligase
Pathway:	PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro

H₂O : 200 mg/mL (708.59 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.5430 mL	17.7148 mL	35.4296 mL
	5 mM	0.7086 mL	3.5430 mL	7.0859 mL
	10 mM	0.3543 mL	1.7715 mL	3.5430 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Lenalidomide (sodium), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (sodium) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (sodium) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells^{[1][2]}.

CUSTOMER VALIDATION

- Cell. 2018 Sep 20;175(1):171-185.e25.
- Cancer Cell. 2022 Aug 26;S1535-6108(22)00372-5.
- Nat Cancer. 2022 May;3(5):595-613.
- Nat Commun. 2017 May 22;8:15398.
- Nat Chem Biol. 2021 Jun;17(6):711-717.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Jan Krönke, et, al. Lenalidomide induces degradation of IKZF1 and IKZF3. *Oncoimmunology*. 2014, 3,7.
- [2]. Venumadhav Kotla, et, al. Mechanism of action of lenalidomide in hematological malignancies. *J Hematol Oncol*. 2009, 2, 36.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA